Alopecia Areata | Treatment Algorithms: Claims Data Analysis | US | 2025
Alopecia areata (AA) is an inflammatory autoimmune skin disease characterized by the targeting of anagen hair follicles by the host immune system, resulting in varying degrees of hair loss. Topical / intralesional corticosteroids have historically dominated prescription treatment for AA. However, beginning in 2022, several therapies, all part of the JAK inhibitor family, have gained FDA approval for the treatment of severe AA: Eli Lilly’s Olumiant (baricitinib), Pfizer’s Litfulo (ritlecitinib), and Sun Pharma’s Leqselvi (deuruxolitinib [commercially available as of mid-2025]). With the AA treatment landscape continuing to evolve, this report offers insight into prescribing trends to help new players understand current treatment practices in AA and to define the market niche for emerging products.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed AA patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed AA patients?
- How have Olumiant and Litfulo been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of AA patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of AA patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
Markets covered: United States
Key drugs: Corticosteroids (injectable, oral, topical), minoxidil, finasteride, dutasteride, Litfulo, Olumiant
Key features: Dashboard featuring interactive visuals, easy navigation, and expanded analyses
Produce enhancement
Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.
